These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2867156)

  • 41. Physiological disposition of verapamil in man.
    Schomerus M; Spiegelhalder B; Stieren B; Eichelbaum M
    Cardiovasc Res; 1976 Sep; 10(5):605-12. PubMed ID: 971476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modified release from hydroxypropyl methylcellulose compression-coated tablets.
    Rujivipat S; Bodmeier R
    Int J Pharm; 2010 Dec; 402(1-2):72-7. PubMed ID: 20883759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both.
    Karim A; Piergies A
    Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose.
    Gohel M; Bariya SH
    Pharm Dev Technol; 2009; 14(6):650-8. PubMed ID: 19883254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preparation and evaluation of 1-deoxynojirimycin sustained-release pellets vs conventional immediate-release tablets.
    Sun Z; Yuan S; Zhao H; Wang Z; Liu Z
    J Microencapsul; 2017 May; 34(3):293-298. PubMed ID: 28425304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leaky enteric coating on ranitidine hydrochloride beads: dissolution and prediction of plasma data.
    Bendas ER; Ayres JW
    Eur J Pharm Biopharm; 2008 Aug; 69(3):977-85. PubMed ID: 18424095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nateglinide controlled release tablet containing compressionable enteric coated granules.
    Makino C; Sakai H; Yabuki A
    Chem Pharm Bull (Tokyo); 2010 Sep; 58(9):1136-41. PubMed ID: 20823590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Formulation and evaluation of dextromethorphan hydrobromide sustained release tablets.
    Meyyanathan SN; Rajan S; Muralidaharan S; Siddaiah MK; Krishnaraj K; Suresh B
    Drug Deliv; 2008 Sep; 15(7):429-35. PubMed ID: 18712620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and in vitro/in vivo evaluation of sustained-release floating tablets of itopride hydrochloride.
    Ahmed SM; Ahmed Ali A; Ali AM; Hassan OA
    Drug Des Devel Ther; 2016; 10():4061-4071. PubMed ID: 28008229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydroxypropyl methylcellulose based cephalexin extended release tablets: influence of tablet formulation, hardness and storage on in vitro release kinetics.
    Saravanan M; Sri Nataraj K; Ganesh KS
    Chem Pharm Bull (Tokyo); 2003 Aug; 51(8):978-83. PubMed ID: 12913240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma concentrations of S-verapamil after single doses of two different galenic formulations of racemic verapamil.
    Harder S; Siewert M; Thürmann P; Blume H; Rietbrock N; Siewert B
    Arzneimittelforschung; 1993 May; 43(5):520-2. PubMed ID: 8328995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs].
    Chen ZP; Xiao YY; Chen HX; Chen XJ; Li LR; Zhu JB
    Yao Xue Xue Bao; 2006 Aug; 41(8):765-71. PubMed ID: 17039785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
    Maurer JM; Schellekens RC; van Rieke HM; Stellaard F; Wutzke KD; Buurman DJ; Dijkstra G; Woerdenbag HJ; Frijlink HW; Kosterink JG
    J Control Release; 2013 Dec; 172(3):618-24. PubMed ID: 24096020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs.
    Yassin AE; Alkhaled F; al-Suwayeh S; Elkheshen S
    Boll Chim Farm; 2003 Sep; 142(7):285-9. PubMed ID: 14677272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The bioavailability of a slow-release verapamil formulation.
    Norris RJ; Muirhead DC; Christie RB; Devane JG; Bottini PB
    Br J Clin Pract Suppl; 1985 Jun; 42():9-16. PubMed ID: 3929828
    [No Abstract]   [Full Text] [Related]  

  • 57. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation.
    Roth W; Setnik B; Zietsch M; Burst A; Breitenbach J; Sellers E; Brennan D
    Int J Pharm; 2009 Feb; 368(1-2):72-5. PubMed ID: 18992310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation.
    Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ibuki R; Higaki K; Kimura T
    J Control Release; 2006 May; 112(1):51-6. PubMed ID: 16545477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Per-oral extended-release bioadhesive tablet formulation of verapamil HCl.
    Elkheshen S; Yassin AE; Alkhaled F
    Boll Chim Farm; 2003 Jun; 142(5):226-31. PubMed ID: 14526657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release.
    Gong L; Sun Y; Yu M; Gao Y; Zou M; Cheng G
    AAPS PharmSciTech; 2018 Oct; 19(7):3277-3286. PubMed ID: 30215168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.